CN1872236A - Medication for treating aplastic anemia - Google Patents
Medication for treating aplastic anemia Download PDFInfo
- Publication number
- CN1872236A CN1872236A CNA2005100135688A CN200510013568A CN1872236A CN 1872236 A CN1872236 A CN 1872236A CN A2005100135688 A CNA2005100135688 A CN A2005100135688A CN 200510013568 A CN200510013568 A CN 200510013568A CN 1872236 A CN1872236 A CN 1872236A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- pharmaceutical composition
- gypsum fibrosum
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
A Chinese medicine for treating aplastic anemia is prepared from 17 Chinese-medicinal materials including ginseng, astragalus root, wolfberry fruit, honeysuckle flower, etc.
Description
Technical field:
The present invention is a kind of medicine for the treatment of aplastic anemia, is to be prepared from by Chinese medicine, belongs to the field of Chinese medicines.
Background technology:
Aplastic anemia is a kind of difficult disease clinically, has very big difficulty in treatment, and people have carried out a large amount of scientific researches in order to capture the treatment difficulty of aplastic anemia for these years.
China studies confirm that for many years through the white jade tablet of inventor: human aplastic anemia is because the patient wears very little clothes, suffer excessive cold, wind and cold to the marrow, resistance descends, and immunologic hypofunction rests on behind the human body virus of nasal meatus and begins breeding and duplicate, virus is invaded the human bone marrow, bone marrow is subjected to the infringement of virus, causes bone marrow suppression system, and the bone marrow pluripotent stem cell is impaired.Therefore, pancytopenia, the microcirculatory substrate of bone marrow is undermined, bone marrow hematogenesis microcirculation movable and bone marrow has substantial connection, and the blood vessel of supplying bone marrow is from nutrient artery, the continuous branch of nutrient artery, flow directly into sinusoid by small artery, it is netted that sinusoid is polygon.At last by this special microcirculation structure of venous return, the Oxygenated blood and the necessary material of hemopoietic of fast flow have been guaranteed to supply, the reparation of hemopoietic function must have the microcirculatory foundation of sinusoid, leaning on vein input stem cell not implant lives again, microcirculation could recover hemopoietic again after must be rebuild, rebuilding microcirculatory normally is the essential condition of hemopoietic, and the microcirculatory infringement of bone marrow is one of pathogeny of aplastic anemia.
The present invention is through research for many years, a kind of medicine for the treatment of aplastic anemia, can repair damaged bone marrow stem cell again, repair bone marrow microcirculation structure, antiviral, antibiotic, again recover bone marrow pluripotent stem cell function and recover the immunologic function of Patients with Aplastic Anemia rapidly, again make the microcirculatory foundation of bone marrow, recover hemopoietic function again, the patient is fully recovered, determined curative effect is worthy to be popularized.
The inventor observes by the treatment of aplastic anemia based on for many years clinical experience, develops a kind of medicine that can effectively treat aplastic anemia.
The purpose of this invention is to provide a kind of medicine for the treatment of aplastic anemia.
The composition of pharmaceutical composition of the present invention is as described below by weight:
10～20 parts of Radix Ginsengs, 10～20 parts of the Radixs Astragali, 10～20 parts of the Rhizoma Atractylodis Macrocephalaes, 10～20 parts of Fructus Lycii, 5～15 parts of Os Draconis, 20～40 parts of Flos Loniceraes, 1～5 part in Gypsum Fibrosum, 10～30 parts in Colla Corii Asini, 10～30 parts of Colla cornus cervis, 1～5 part of Carapax Trionycis, 2～10 parts in Radix Glycyrrhizae
The preferential proportioning of aforementioned pharmaceutical compositions of the present invention is:
12～17 parts of Radix Ginsengs, 12～17 parts of the Radixs Astragali, 12～17 parts of the Rhizoma Atractylodis Macrocephalaes, 12～17 parts of Fructus Lycii, 7～12 parts of Os Draconis, 25～35 parts of Flos Loniceraes, 2～4 parts in Gypsum Fibrosum, 12～15 parts in Colla Corii Asini, 12～15 parts of Colla cornus cervis, 2～4 parts of Carapax Trionycis, 3～8 parts in Radix Glycyrrhizae
The best proportioning of above-mentioned composition of the present invention is:
15 parts of Radix Ginsengs, 15 parts of the Radixs Astragali, 15 parts of the Rhizoma Atractylodis Macrocephalaes, 15 parts of Fructus Lycii, 10 parts of Os Draconis, 30 parts of Flos Loniceraes, 3 parts in Gypsum Fibrosum, 15 parts in Colla Corii Asini, 15 parts of Colla cornus cervis, 3 parts of Carapax Trionycis, 6 parts in Radix Glycyrrhizae
Pharmaceutical composition of the present invention can also add following medicine:
10～20 parts of Radix Codonopsis, 8～14 parts of Fructus Ligustri Lucidi, 8～14 parts of Semen Cuscutae, 8～14 parts of the Pseudobulbus Bletillae (Rhizoma Bletillae)s, 8～14 parts in Poria, 8～14 parts in Fructus Jujubae
Its optimum ratio of the component of above-mentioned increase is as follows:
12～18 parts of Radix Codonopsis, 9～12 parts of Fructus Ligustri Lucidi, 9～12 parts of Semen Cuscutae, 9～12 parts of the Pseudobulbus Bletillae (Rhizoma Bletillae)s, 9～12 parts in Poria, 9～12 parts in Fructus Jujubae
The best proportioning of the component of above-mentioned increase is:
15 parts of Radix Codonopsis, 10 parts of Fructus Ligustri Lucidi, 10 parts of Semen Cuscutae, 10 parts of the Pseudobulbus Bletillae (Rhizoma Bletillae)s, 10 parts in Poria, 10 parts in Fructus Jujubae
The preferred Radix Ginseng Rubra of Radix Ginseng in the middle of the aforementioned pharmaceutical compositions of the present invention, Gypsum Fibrosum preferably uses Gypsum Fibrosum, and Os Draconis preferably use Os Draconis.
Pharmaceutical composition of the present invention can add medical dressing commonly used as active component, is prepared into the various dosage forms that are suitable for clinical use, for example: granule, tablet, oral liquid, capsule, pill etc.
The preparation method of drug particles of the present invention is as follows:
The Radix Ginseng powder is broken into smalls, make filler for starch, Colla Corii Asini and Colla cornus cervi fine powder are broken, all the other Flos Loniceraes etc. are decocted with water extract twice, twice water consumption and be respectively 10 times of amounts and 8 times of amounts, extraction time is two hours, merging filtrate, being concentrated into proportion is 1.35～1.38, adds Radix Ginseng, Colla Corii Asini, Colla cornus cervi fine powder, is drying to obtain.
By zoopery and Clinical detection and observation of curative effect; a kind of medicine for the treatment of aplastic anemia of medicine of the present invention; the effect of protection human normal cell and bone marrow is arranged; repair the normal cell of due to illness poison infringement and the damage of each system; can improve immunologic function rapidly; recover the bone marrow stem cell hemoposieis, antibiotic, antiviral.
Experimental example: a kind of medicine for the treatment of aplastic anemia, clinical observation object and method:
Aplastic anemia is to cause because of the bone marrow hematogenesis tissue significantly reduces, depleted and the class anemia that takes place of hemopoietic function, as long as early stage active treatment, significant to cure diseases, a kind of medicine for the treatment of aplastic anemia of the present invention's development can be repaired bone marrow microcirculation structure again, recover hemopoietic function, the patient fully recovered, now observed result is reported as follows:
The case choice criteria:
(1) diagnostic criteria: this organizes selected case is based on various deficient syndromes, excellent in yang deficiency, the deficiency of vital energy is main performance, wherein whole blood minimizing, cardiopalmus, breathe hard, susceptible to lose temper due to restlessness, weak, uncomfortable in chest, spontaneous perspiration, night sweat, lumbago and skelalgia, inappetence, aversion to cold and cold limbs, wherein with anemia, pale complexion, breathe hard, weak comparatively see more.
(2) therapeutic effect:
1. medicine is formed: a kind of medicine for the treatment of aplastic anemia, pure Chinese medicinal preparation.(can claim the aplastic anemia spirit)
2. usage: be 30 per course of treatment, generally obeyed for 3～5 courses of treatment.Period in a medicine any other medicine of stopping using, the patient needs antiinflammatory if any inflammation.
3. curative effect determinate standard:
1. recovery from illness: symptom all disappears, and immunologic function obviously improves, and complete blood cell reaches normal value, the good result of total effective rate 98.6%.
2. invalid: symptom, whole blood and immunologic function index no change.
Model case: Zhang, male, 26 years old, army provisions city, Tianjin power plant workman, be diagnosed as chronic aplastic anemia.I go to a doctor blood test pigment 7.2g/L, erythrocyte 28 * 10 at institute over 1989
12/ L leukocyte 3.2 * 10
9/ L, platelet 50 * 10
9/ L, begin to obey the aplastic anemia spirit, every day three times, each five parcels, boiled water is taken after mixing it with water, transference cure behind the first quarter moon, appetite increases, weight increase.Blood test pigment 14.6g/L, erythrocyte 48 * 10 after half a year
12/ L leukocyte 8 * 10
9/ L, platelet 30 * 10
9/ L, continuing again takes medicine consolidates one section, resumes work after nineteen ninety, May was in vigorous health, and marry and give birth to babies in August, 1993, recovery from illness.
The specific embodiment:
Embodiment 1 side's medicine: Radix Ginseng 10 grams, the Radix Astragali 10 grams, the Rhizoma Atractylodis Macrocephalae 10 grams, Fructus Lycii 10 grams, Os Draconis 15 grams, Gypsum Fibrosum 3 grams, Flos Lonicerae 20 grams, Colla Corii Asini 15 grams, Colla cornus cervi 15 grams, Carapax Trionycis 3 grams, Radix Glycyrrhizae 6 grams
Said medicine decocts with water twice, and amount of water did not have powder, decocts one hour at every turn, merges decoction liquor twice, is condensed into extractum, oven dry, system granule.
Embodiment 2 side's medicines: Radix Ginseng 15 grams, the Radix Astragali 15 grams, the Rhizoma Atractylodis Macrocephalae 15 grams, Fructus Lycii 15 grams, Os Draconis 15 grams, Gypsum Fibrosum 3 grams, Flos Lonicerae 15 grams, Colla Corii Asini 15 grams, Colla cornus cervi 15 grams, Carapax Trionycis 3 grams, Radix Glycyrrhizae 6 grams
Radix Ginseng powder is broken into smalls, makes filler for starch, Colla Corii Asini and Colla cornus cervi fine powder are broken, all the other Flos Loniceraes etc. are decocted with water, extract twice, twice water consumption and be respectively 10 times of amounts and 8 times of amounts, extraction time is two hours, it is 1.35～1.38 that merging filtrate is concentrated into proportion, adding Radix Ginseng, Colla Corii Asini, Colla cornus cervi fine powder are lived even, make granule, drying, be ground into 80 purpose powder again, be drying to obtain.
Embodiment 3 side's medicines: Radix Ginseng 15 grams, the Radix Astragali 15 grams, the Rhizoma Atractylodis Macrocephalae 15 grams, Fructus Lycii 15 grams, Os Draconis 15 grams, Gypsum Fibrosum 3 grams, Flos Lonicerae 30 grams, Colla Corii Asini 15 grams, Colla cornus cervi 15 grams, Carapax Trionycis 3 grams, Radix Codonopsis 15 grams, Fructus Ligustri Lucidi 10 grams, Semen Cuscutae 10 grams, the Pseudobulbus Bletillae (Rhizoma Bletillae) 10 grams, Poria 10 grams, Fructus Jujubae 10 grams, Radix Glycyrrhizae 6 grams
Ten four Chinese medicines such as extracting honeysuckle decoct with water twice, add 8 times of amounts of water at every turn, decoct filtration in 30 minutes at every turn, merge filtrate twice, are concentrated into about 1: 1, and Radix Ginseng, Colla Corii Asini, Colla cornus cervi are pulverized.
More than the chilled concentrated solution amount of doubling ethanol, and be concentrated into 1: 4-5.
With extractum, Icing Sugar, dextrin 21: 3 or 1-1.5, uniform mixing (adding a small amount of 75% ethanol in case of necessity) is made soft material, granulates oven dry below 80 degree, granulate packing with the 10-12 mesh sieve.
Claims (10)
1. pharmaceutical composition is characterized in that the composition of said composition and quality proportioning thereof are:
Radix Ginseng 10～201 minutes, 10～20 parts of the Radixs Astragali, Rhizoma Atractylodis Macrocephalae 10-20 part,
Fructus Lycii 10-20 part, Os Draconis 5-15 part, 20～40 parts of Flos Loniceraes,
Gypsum Fibrosum 1-5 part, 10～15 parts in Colla Corii Asini, 10～15 parts of Colla cornus cervis,
1～5 part of Carapax Trionycis, 2～10 parts in Radix Glycyrrhizae
2. according to the pharmaceutical composition of claim 1, it is characterized in that the total amount ratio of said composition is:
12～17 parts of Radix Ginsengs, 12～17 parts of the Radixs Astragali, 12～17 parts of the Rhizoma Atractylodis Macrocephalaes,
12～17 parts of Fructus Lycii, Os Draconis 7-12 part, 25～35 parts of Flos Loniceraes,
2～4 parts in Gypsum Fibrosum, 12～15 parts in Colla Corii Asini, 12～15 parts of Colla cornus cervis,
2～4 parts of Carapax Trionycis, 3～8 parts in Radix Glycyrrhizae
3. according to the pharmaceutical composition of claim 2, it is characterized in that the total amount ratio of said composition is:
15 parts of Radix Ginsengs, 15 parts of the Radixs Astragali, 15 parts of the Rhizoma Atractylodis Macrocephalaes, 15 parts of Fructus Lycii,
10 parts of Os Draconis, 30 parts of Flos Loniceraes, 3 parts in Gypsum Fibrosum, 15 parts in Colla Corii Asini,
15 parts of Colla cornus cervis, 3 parts of Carapax Trionycis, 6 parts in Radix Glycyrrhizae
4. according to the pharmaceutical composition of claim 1, it is characterized in that said composition also comprises following medicine:
10～20 parts of Radix Codonopsis, 8～14 parts of Fructus Ligustri Lucidi, Semen Cuscutae 8-14 part,
Pseudobulbus Bletillae (Rhizoma Bletillae) 8-14 part, 8～14 parts in Poria, 8～14 parts in Fructus Jujubae
5. according to the pharmaceutical composition of claim 4, it is characterized in that to increase the total amount proportioning of component as follows:
12～18 parts of Radix Codonopsis, 9～12 parts of Fructus Ligustri Lucidi, 9～12 parts of Semen Cuscutae,
9～12 parts of the Pseudobulbus Bletillae (Rhizoma Bletillae)s, 9～12 parts in Poria, 9～12 parts in Fructus Jujubae
6. according to the pharmaceutical composition of claim 5, it is characterized in that to increase the total amount proportioning of component as follows:
15 parts of Radix Codonopsis, 10 parts of Fructus Ligustri Lucidi, 10 parts of Semen Cuscutae,
10 parts of the Pseudobulbus Bletillae (Rhizoma Bletillae)s, 10 parts in Poria, 10 parts in Fructus Jujubae
7. according to the pharmaceutical composition of one of claim 1～7, it is characterized in that above-described Radix Ginseng uses Radix Ginseng Rubra, Gypsum Fibrosum uses Gypsum Fibrosum.
8. pharmaceutical preparation is characterized in that said preparation is an active component with the pharmaceutical composition of one of claim 1～7, adds dressing and is prepared from.
9. pharmaceutical preparation according to Claim 8 is characterized in that above-described Radix Ginseng uses Radix Ginseng Rubra, and Gypsum Fibrosum uses Gypsum Fibrosum, and Os Draconis use Os Draconis.
10. pharmaceutical preparation according to Claim 8, it is characterized in that above-described preparation be selected from the middle of the granule, tablet, oral liquid, capsule, pill a kind of.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2005100135688A CN1872236A (en) | 2005-05-30 | 2005-05-30 | Medication for treating aplastic anemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2005100135688A CN1872236A (en) | 2005-05-30 | 2005-05-30 | Medication for treating aplastic anemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1872236A true CN1872236A (en) | 2006-12-06 |
Family
ID=37482945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2005100135688A Pending CN1872236A (en) | 2005-05-30 | 2005-05-30 | Medication for treating aplastic anemia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1872236A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103405603A (en) * | 2013-08-26 | 2013-11-27 | 费海荣 | Composite drug composition for treating anemia |
| CN104491519A (en) * | 2014-12-08 | 2015-04-08 | 吕凤荣 | Yin-nourishing and qi-tonifying preparation for aplastic anemia due to dual depletion of qi and blood and preparation method |
| CN105343320A (en) * | 2015-11-20 | 2016-02-24 | 王立鑫 | Health preserving syrup with mind tranquillizing and sleep aiding efficacy |
-
2005
- 2005-05-30 CN CNA2005100135688A patent/CN1872236A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103405603A (en) * | 2013-08-26 | 2013-11-27 | 费海荣 | Composite drug composition for treating anemia |
| CN104491519A (en) * | 2014-12-08 | 2015-04-08 | 吕凤荣 | Yin-nourishing and qi-tonifying preparation for aplastic anemia due to dual depletion of qi and blood and preparation method |
| CN105343320A (en) * | 2015-11-20 | 2016-02-24 | 王立鑫 | Health preserving syrup with mind tranquillizing and sleep aiding efficacy |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100457176C (en) | Chinese medicinal preparation for curriculum of physical and fatigue reducing | |
| CN101130030A (en) | Medicine composition for treating nephropathy and uses of the same | |
| CN101972454A (en) | Medicament for treating lymphoma | |
| CN101011522B (en) | Chinese traditional medicine for treating cardiopathy | |
| CN101041046A (en) | Chinese traditional medicine compound took orally for treating morning diarrhea | |
| CN1846772A (en) | Uremia treating Chinese medicine | |
| CN102579610B (en) | Chinese medicinal composition for treating cerebral hemorrhage and preparation method thereof | |
| CN1872236A (en) | Medication for treating aplastic anemia | |
| CN101041006A (en) | Composite Chinese medicine took orally for treating coronary heart disease | |
| CN101239159B (en) | Chinese medicinal composition for treating rheumatoild disease and preparation thereof | |
| CN102416121B (en) | Application of medicinal composition in preparation of medicaments for treating gastric ulcer | |
| CN104906430A (en) | Traditional Chinese medicine preparation for treating xerophthalmia and preparation method thereof | |
| CN104587398A (en) | Microorganism fermented traditional Chinese medicinal preparation as well as preparation method and application thereof | |
| CN104587267A (en) | Traditional Chinese medicine composition for treating psoriasis | |
| CN101066379A (en) | Chinese medicine composition for treating fever during menstruation | |
| CN1180821C (en) | Medicine for treating cerebral thrombus and its prepn | |
| CN1127344C (en) | Oral pill for curing diabetes and its complication | |
| CN102430073B (en) | Medicinal composition for treating peptic ulcer | |
| CN102416120B (en) | Application of medicinal composition in preparation of medicament for treating erosive gastritis | |
| CN101637536B (en) | Medicine for treating chronic sinusitis and preparation method thereof | |
| CN1245197C (en) | Chinese medicine preparation for treating coronary heart disease and viral myocarditis | |
| CN101199667A (en) | Chinese medicine for treating leukemia, aplastic anemia | |
| CN1271590A (en) | Medical capsule for curing aplastic anemia and its preparing process | |
| CN1425456A (en) | Nourishing wine for regulating human body balance function | |
| CN1279951C (en) | Pure Chinese traditional medicine capsule for treating hyperthyroidism and simple goiter |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20061206 |